Non-GAAP R&D expense in the third quarter of 2021 was 9% versus 9.2% in Q3 of 2020.
Sales of the Life Science Group in the third quarter of 2021 were $373.5 million compared to $324 million in Q3 of 2020, which is a 15.3% increase on a reported basis and a 13.9% increase on a currency-neutral basis.
Excluding the back royalties, the Q3 year-over-year currency-neutral revenue growth was 9%.
Moving on to the non-GAAP results.
The effective tax rate for the third quarter of 2021 was 21.8% compared to 21.9% for the same period in 2020.
